Therapeutic developments in metabolic dysfunction-associated fatty liver disease.

Area of Science:

• Hepatology
• Metabolic Disorders
• Internal Medicine

Background:

• Metabolic dysfunction-associated fatty liver disease (MAFLD) is a prevalent global liver condition.
• MAFLD increases risks for cirrhosis, liver cancer, and cardiovascular events.
• Effective pharmacological treatments for MAFLD are still lacking.

Purpose of the Study:

• To review current therapeutic strategies for MAFLD.
• To highlight individualized treatment approaches based on patient metabolic profiles.
• To provide insights into managing MAFLD through weight loss, insulin resistance improvement, and cardiometabolic disorder management.

Main Methods:

• Literature review of current research on MAFLD treatments.
• Analysis of therapeutic benefits based on patient comorbidities like type 2 diabetes and obesity.
• Synthesis of information on weight loss, insulin resistance, and cardiometabolic management.

Main Results:

• MAFLD patients with type 2 diabetes benefit from anti-hyperglycemic agents.
• Overweight and obese MAFLD patients show improved outcomes with weight loss therapies.
• Comprehensive management of metabolic syndrome is crucial for reducing adverse outcomes.

Conclusions:

• Individualized treatment is key for managing MAFLD and its associated risks.
• Therapeutic strategies should target weight loss, insulin sensitivity, and cardiometabolic health.
• Further research into effective drug therapies for MAFLD is warranted.